Glioblastoma in natalizumab-treated multiple sclerosis patients

Fabian Sierra Morales, Robert B. Wright, Jorge Novo, Leonidas D. Arvanitis, Dusan Stefoski, Igor J. Koralnik*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

We present two natalizumab-treated multiple sclerosis patients who developed glioblastoma multiforme (GBM) with variable outcomes. One patient had an isocitrate dehydrogenase (IDH)-wildtype GBM with aggressive behavior, who declined treatment and died 13 weeks after symptoms onset. The other patient underwent resection of an IDH-mutant secondary GBM that arose from a previously diagnosed grade II astrocytoma. He is still alive 5 years after the diagnosis of GBM. JC virus was not detected in either case. Whether natalizumab played a role in the development of GBM in those patients deserves further investigation.

Original languageEnglish (US)
Pages (from-to)512-516
Number of pages5
JournalAnnals of clinical and translational neurology
Volume4
Issue number7
DOIs
StatePublished - Jul 1 2017

Funding

We thank Dr. Eugene Major from NINDS for performing JC Virus PCR testing in brain sample from patient one. This work was supported in part by grants of the National Institutes of Health R01 NS 047029 and R01 NS 074995 to IJK.

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Glioblastoma in natalizumab-treated multiple sclerosis patients'. Together they form a unique fingerprint.

Cite this